Evaluation of Her- 2 neu over expression in morphological variants of cervical carcinomas using immunohistoichemistry: A study of 25 cases.

  • Nimisha Sharma VMMC and Safdarjung Hospital, GGSIPU
  • Ankit Kaushik VMMC and SJH, Delhi
  • Sumanashree . VMMC and SJH hospital
  • Uma Sharma STG Medical College, Gurgaon
Keywords: Her- 2 neu, cervical carcinomas, immunohistoichemistry

Abstract

Introduction: Carcinoma of uterine cervix is the second most prevalent cancer among women worldwide and remains a major gynecological malignancy in developing countries. HER-2/neu,a pro-oncogene is a cell membrane surface bound tyrosine kinase receptor  and is involved in signal transduction pathway leading to cell growth and differentiation.Aim: The present study is conducted to evaluate the over-expression of HER-2/neu in carcinoma cervix, its pattern of membranous staining and correlation with histological type, grade of tumor and stage of disease wherever available.Methods: A part retrospective and part prospective study was done on a total of 25 cervical biopsies and hysterectomies specimen. Tissue blocks with extensive necrosis or hemorrhage were excluded from the study and  immunohistochemistry  for HER-2/neu was done. The percentage of cells showing the membranous positivity for HER2/neu, extent of its positivity in the cervical epithelium in different lesions of the cervix and membranous intensity of HER2/neu positive cells was noted. The HER2/neu expression was then correlated with morphological diagnosis, grade of lesion, invasion and lymph node metastasis in hysterectomies.Results: 18 cases were reported to be SCC (72%) , while Adenocarcinoma (12%)  and Adenosquamous (16%) carcinoma constituted small subgroups of 3 and 4 cases, respectively,  13(52%)  cases of carcinoma cervix were found to be positive for HER 2/neu while 12/25 cases(48%) were negative. 11 cases of SCC were positive for HER2/neu, 2/4 adenosquamous carcinoma cases  were positive. No adenocarcinoma cases were found to be  positive  for HER2/neu.                         12 carcinoma cervix cases show <10%  cells  staining for HER2 /neu (48%). 9 cases involved 10-20% of cells (36%), while only four cases had positive cell count > 20% (6%). Of the 19 of carcinoma cervix with known staging,  (9)  were of stage 1, 1/9 cases of stage I   showed HER2/neu positivity (2+),  4/6 of stage II were moderately positive (2+) for the marker 2/ 2 of  stage IV cases showed 2+ and 3+ positivity.The present study showed SCC to be the most common carcinoma with 52% of carcinoma cervix cases expressed positivity for HER-2/neu. Maximum number of carcinoma cases showed 2+ HER-2/neu  intensity. HER-2/neu positivity was found to be highest in SCC, followed by adenosquamous and adenocarcinoma. Her 2/neu was found to be over expressed in higher stage with high percentage positivity.Conclusion: The high incidence of HER-2/neu  amplification  in  cervical  cancer suggests the role of this gene in tumorigenesis and this study emphasize HER-2/neu overexpression in cervical carcinoma.                        

References

1. Shanta V, Krishnamurthy S, Gajalakshmi CK, Swaminathan R, Ravichandran K. Epidemiology of cancer of the cervix: global and national perspective. J Indian Med Assoc; 2000;98:49-52.
2. Rotkin, I. D. Relation of adolescent coitus to cervical cancer risk. Journal of the American Medical Association;1962;179,486.
3. Fauci S, Braunwald E , Kasper D, Hauser SL, Lengo D, Jameson JL et al. Gynecologic Malignancy in Harrison’s Principles of Internal Medicine. Seventeenth Ed.USA: Mc Graw-Hill; 2008;604-609.
4. Kumar V, Abbas AK, Fausto N, Astor JC,. Female Genital Tract in Robbins and Cotran Pathologic Basis of Disease. Eighth Ed. Philadelphia: Elsevier; 2010;1020-1025.
5. Hung MC, Matin A, Zhang Y, Xing X, Sorgi F, Huang L, et al. HER-2/neu-targeting gene therapy-a review. Gene 1995;159:65-71.
6. Duenas-Gonzalez A, Cetina l, Mariscal I, Garza J. Cancer Treat Rev. 2003;29(5):389-99.
7. Ray A, Naik SL, Sharma BK. Distribution of prognostically unfavourable product of C-erb B-2 oncogene and EGFR in carcinomas of breast and the uterine cervix. Indian J Physiol Pharmacol 2002;46:423-33.
8. Popescu, N. C., King, C. R., and Kraus, M. H. Localization of the human erbB2 gene on normal and rearranged chromosomes 17 to bands q12.2l.32. Genomics, 4:362- 366,1989.
9. Bargmann CL, Hung MC, Weinberg RA. The new oncogene encodes an epidermal growth factor receptor-related protein. Nature;1986;4:362-6.
10. Nevin J, Liang D, Kaye P, McCulloch T. The Significance of ErbB-2 Immunostaining in Cervical Cancer. Gyenecologic Oncology. 1999;73:354-358.
11. Mitra A B,Murty VVVS, Pratap M, Sodhani P, Chaganti R S K.ErbB-2 (HER2/neu) Oncogene is frequently amplified in Squamous Cell Carcinoma of the Uterine Cervix. Cancer Research. 1994; 54: 637-639.
12. Nakano T, Oka K, Morita S. Correlation of cervical carcinoma c-erbB2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma. Cancer 1997;79:513-20.
13. Gupta N, Singh S, Marwah N, Kumar S, Chabra S, Sen R.HER-2/neu Expression in Lesion of Uterine Cervix; Is It Reliable and Consistent? Indian J Pathol Micro. 2009; 52(4):482-485.
14. Marwah N, Garg M, Singh S, Sethi D, Sen R. Unusual form of squamous cell carcinoma of the cervix extending in situ into the endometrium: Three case reports and review of literature. Int J App Basic Med Res 2012;2:139-41
15. Ray A, Naik S. L. D. and Sharma B. K. Distribution of prognostically unfavourable product of c-erbB-2 oncogene and EGF-R in carcinomas of the breast and uterine cervix. Indian J Physiol Pharmacol 2002; 46(4):423-33.
16. Graham J.B. Characteristics of women with various gynaecological cancers.Obstetrics and Gynecology, 1964;23,176.
17. Horton J: Trastuzumab use in breast cancer: clinical issues. Cancer Control 2002, 9:499-507.
18. Bethwaite P, Yeong M 1, Holloway 1 et al1992. The prognosis of adenosquamous carcinoma of the uterine cervix. Br J Obstet Gynaecol99: 745-750.
19. Goud KI, Dayakar S, Vijyalaxmi K, Babu SJ, Vijay ARP. Evaluatiion of HER-2/neu status in breast cancer specimens using immunohistochemistry (IHC) & fluorescence in-situ hybridization (FISH) assay. The Indian Journal of Medical Research.2012;135(3):312-7.
20. Rosty C, Couturier J, Genin P. et al. Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of uterine cervix. Int J Gynecol Pathol. 2004;23(1):13-17.
21. Hale R J,Buckley C H,Fox H,Williams J.Prognostic value of c-erbB-2 in expression of Uterine Cervical Carcinoma. J Clin Pathol. 1992; 45: 594-596.
22. Califano D, Losito S, Pisano C. et al. Significance of erbB-2 immunoreactivity in cervical cancer.Front Biosci, 2006 sep 1;11:2071-6.
23. Nadubisi B, Sanz S et al. The prognostic value of HER-2/neu oncogene in cervical cancer.Ann Clin Lab Sci. 1997;27:396-401.
24. Alma Chavez-Blanco, Victor Perez-Sanchez et al. HER-2/neu expression in cervical cancer as a potential therapeutic target. BMC cancer 2004;4:59.
25. Kersemaeckers AF, Fleuren G J, Kenter G G, Broek LV, Uljee SM, Hermans J et al.Oncogene overexpression of Epidermal Growth Factor Receptor is associated with poor prognosis.Clinical Cancer Research. 1999; 5: 577-586.
26. Wong, A. J., Ruppert, J. M., Eggleston, J., Hamilton, S. R., Baylin, S. B., and Vogelstein, B. Gene amplification of C-myc and N-myc in small cell carcinoma of the lung. Science (Washington DC), 233: 461—464, 1986.”8201,991.
27. Brumm C, Riviere A, Wilckens C: Immunohistochemical investigation and northern blot analysis of c-erb B2 expression in normal,premalignant and malignant tissue of cervix uteri.Virchow archeive pathol Anat. 417:477-484,1990.
28. Kihana T, Tsuda H,Teshima S, Nomoto K, Tsugane S, Sonada T et al.Prognostic Significance of over expression of c-erbB-2 Protein in Adenocarcinoma of Uterine Cervix. Cancer. 1994; 73(1): 148-153.
Published
2016-06-27
Issue
Vol 3 No 2 (2016)
Section
Original Article

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).